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Introduction {#sec007}
============

Type 2 diabetes (T2D) constitutes a growing global epidemic worldwide and is associated with numerous disabling and life-threatening complications, as well as a major economic burden \[[@pone.0138646.ref001]\]. Individuals with impaired fasting glucose homeostasis and/or impaired glucose tolerance (referred to as pre-diabetic) are at high risk for the future development of T2D, especially if they are also overweight \[[@pone.0138646.ref001]--[@pone.0138646.ref004]\]. Moreover, micro- and macrovascular damage is already present in pre-diabetic individuals \[[@pone.0138646.ref005]--[@pone.0138646.ref009]\]. Preventing or delaying progression to T2D in this population is therefore a major public health issue and therapeutic goal \[[@pone.0138646.ref008]--[@pone.0138646.ref010]\]. Recommendations include lifestyle interventions (i.e. switch to a healthier diet and increased physical activity), and use of various medications \[[@pone.0138646.ref003]--[@pone.0138646.ref010]\]. However, lifestyle interventions are difficult to maintain in the long term and medications may be associated with side effects \[[@pone.0138646.ref007]--[@pone.0138646.ref009]\].

Nutraceuticals may represent a valuable alternative or adjunct to conventional prescription drugs in such a context. Among these, cinnamon has been shown to possess anti-diabetic and anti-inflammatory properties in experimental studies \[[@pone.0138646.ref011]--[@pone.0138646.ref014]\]. However, despite promising initial findings in T2D patients \[[@pone.0138646.ref015]\], subsequent clinical studies have generated conflicting results, probably owing to differences in the population included, dose range, dosage form, treatment duration, confounding concomitant treatments and quality of study design \[[@pone.0138646.ref016]--[@pone.0138646.ref020]\]. To the best of our knowledge, only one study has evaluated the effect of cinnamon in pre-diabetic subjects, showing that this was effective in lowering fasting plasma glucose (FPG) and oxidative stress \[[@pone.0138646.ref021]\], and might therefore be able to prevent or delay progression to T2D \[[@pone.0138646.ref021];[@pone.0138646.ref022]\]. Chromium, an essential mineral, has been proposed to act as a regulator of glycemic homeostasis with an effect on HbA1c \[[@pone.0138646.ref023]--[@pone.0138646.ref025]\]. Another micronutrient candidate that could also be considered in this context is carnosine, a naturally occurring compound with antiglycation and anti-aging activities \[[@pone.0138646.ref026]\], which might potentiate any favorable effect of cinnamon on glycemic control in pre-diabetic subjects. Finally, both cinnamon and chromium have been suggested to have favorable effects on body composition \[[@pone.0138646.ref021];[@pone.0138646.ref027]\].

We therefore conducted a randomized, double-blind, placebo-controlled study to evaluate the effects of a 4-month treatment with a micronutrient dietary supplement containing cinnamon, chromium and carnosine in overweight or obese pre-diabetic subjects, with change in FPG level as the primary outcome. Glycemic control, insulin sensitivity, adiposity, lipid profile and inflammatory markers were also explored.

Subjects and Methods {#sec008}
====================

Subjects {#sec009}
--------

Subjects were enrolled in the study between November 2011 and April 2012. The last subject completed the study on August 2012. Subjects aged between 25 and 65 years, overweight (body mass index ≥25 kg/m^2^), presenting a FPG level between 5.55 mmol/L and 7 mmol/L \[[@pone.0138646.ref002]\] and unwilling to change their usual dietary and physical activity habits were eligible for randomization.

Subjects with overt diabetes, any abnormality in renal, hepatic or thyroid function, hypogonadism, history of musculoskeletal, autoimmune or neurologic disease, or human immunodeficiency or hepatitis C virus infection, or having experienced weight loss of more than 5% within the previous six months, were excluded. Other exclusion criteria were consumption of any supplement containing cinnamon or chromium, or any current treatment potentially interfering with plasma glucose homeostasis or body weight control. Finally, women of childbearing age were excluded if they were pregnant, breast-feeding, or not using a reliable contraceptive method.

Study design {#sec010}
------------

This was a single center, randomized, double-blind, placebo-controlled, two-parallel group study conducted at the outpatient clinic of the Nutrition Department at the Pitié-Salpêtrière Hospital, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.

Participants were randomized on the basis of a computer-generated list provided by PiLeJe Institute (Saint-Laurent-des-Autels, France) to receive either a micronutrient dietary supplement or placebo for 4 months. Face-to-face follow-up visits were scheduled at 2, 4 (end of treatment period) and 6 (end of study) months from randomization. Participants were instructed to maintain their usual lifestyle during the experimental period.

The study was conducted according to the ethical principles of the Declaration of Helsinki and local regulations. The protocol was approved by the independent ethics committee of Pitié-Salpêtrière Hospital on December 1^st^, 2010, and obtained the authorization of the French agency for the security of medications and health products--Afssaps changed to ANSM on 2 November 2010. A written informed consent was obtained from all patients before inclusion. This clinical trial was registered before enrollment of participants in the EU Clinical trials Register under the identification number: ID RCB 2010-A00776-33. It was also registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) under the identification number: NCT01530685 (URL: [clinicaltrials.gov/show/NCT01530685?displayxml=true](http://clinicaltrials.gov/show/NCT01530685?displayxml=true)) later due to some technical problems with the sponsor of the study. The authors confirm that all ongoing and related trials for this drug/intervention are registered.

Treatments {#sec011}
----------

Participants received orally, during lunch, two capsules per day of either a dietary supplement, containing: cinnamon, chromium and carnosine (Glycabiane^®^, PiLeJe, Saint-Laurent-des-Autels, France) or placebo ([Table 1](#pone.0138646.t001){ref-type="table"}). The capsules of the placebo and the dietary supplement were identical in colour, form and smell. There was a 100 mg difference in weight between the two capsules, which could not be detected by handling. Therefore, the double-blinded treatment was correctly respected for the subjects and the medical staff. The cinnamon used (ChalCinn^®^, PiLeJe, Saint-Laurent-des-Autels, France) was an extract of cinnamon bark (*Cinnamomum cassia*), rich in polyphenol type-A polymers (oligomeric proanthocyanidins-A: OPC-A). Chromium was used in the form of chromium chloride (Guanylor^®^, PiLeJe, Saint-Laurent-des-Autels, France).

10.1371/journal.pone.0138646.t001

###### Composition of the dietary supplement and placebo capsules.

HPMC: hydroxy-propyl-methylcellulose.

![](pone.0138646.t001){#pone.0138646.t001g}

  Ingredient                           Dietary supplement (Quantity per capsule)   Placebo (Quantity per capsule)
  ------------------------------------ ------------------------------------------- --------------------------------
  **Extract of cinnamon**              228.00 mg                                   \-
  **L-carnosine**                      100.00 mg                                   \-
  **Chromium guanylate**               1.25 mg (10 μg chromium chloride)           \-
  **Excipients**                                                                   
      Silica                           16.00 mg                                    \-
      Talc                             7.00 mg                                     7.00 mg
      Magnesium stearate               6.00 mg                                     6.00 mg
      Hydrated silica                  5.00 mg                                     5.00 mg
      Silicon dioxide                  \-                                          16.00 mg
      Microcristalline cellulose       \-                                          230.25 mg
  **Clear transparent HPMC capsule**   95.00 mg                                    95.00 mg
  **Total**                            **595 mg**                                  **496 mg**

Treatment compliance was assessed by means of a diary in which all capsules taken were to be recorded by the participants, and by counting the number of capsules returned by the participants at the end of the treatment period. Any treatment likely to interfere with glycemic control was prohibited throughout the study.

Outcome measures {#sec012}
----------------

The primary efficacy outcome was the change in FPG level at 4 months. Secondary outcomes were considered as exploratory and included changes at 4 months in other parameters of glucose homeostasis (fasting plasma insulin, plasma glycated hemoglobin \[HbA1c\], and markers of insulin resistance/sensitivity), parameters of lipid homeostasis (plasma triglycerides, total cholesterol, high-density \[HDL\] and low-density \[LDL\] lipoprotein cholesterol, free fatty acids), adiposity markers (body weight, body mass index, fat mass and fat-free mass, adipocyte diameter), adipokines (plasma leptin, adiponectin), and markers of inflammation (high-sensitivity C-reactive protein \[hs-CRP\], interleukin-6 \[IL-6\]) and cardiovascular risk (plasminogen activator inhibitor type 1 \[PAI-1\]). Metabolic activity of adipose tissue *in vitro* (secretion of adiponectin and IL-6, insulin sensitivity estimated by the measurement of serine/threonine protein kinase B \[PKB, also known as Akt\]) was also explored, and dietary intakes and lifestyle were assessed. The safety outcome was the incidence of adverse events, whether serious or not, during the study period.

Participants underwent a series of explorations after a 12-hour overnight fast.

Adipose tissue samples and body composition were analyzed at baseline (Day 0) and at the end of the treatment period (Month 4). A sample of subcutaneous abdominal adipose tissue (SCAT) in the periumbilical area was obtained from each patient on arrival, by needle aspiration (using a 14-gauge needle) under local anesthesia with 10% lidocaine hydrochloride solution not containing epinephrine (Xylocaine^®^, AstraZeneca, Rueil Malmaison, France). Fresh aliquots of this sample were used to measure adipocyte diameter and to explore *in vitro* adipose tissue metabolism. For adipocyte diameter measurement, a portion of each SCAT biopsy sample was immediately isolated by collagenase digestion and cell size measurements were performed as previously described \[[@pone.0138646.ref028]\]. Another portion was cultured for 24 hours, the secretion medium then being collected and frozen at -80°C for determination of IL-6 and adiponectin levels \[[@pone.0138646.ref029]\]. The adipose tissue samples were also used to evaluate insulin sensitivity by measuring insulin stimulation of Akt \[[@pone.0138646.ref030]\].

Body composition (fat and fat-free mass distribution) was determined using dual-energy X-ray absorptiometry (Lunar Prodigy, General Electric Medical Systems, Madison, WI, USA).

At Day 0, Month 4 and Month 6 (end of the follow-up period), blood samples were withdrawn after an overnight fast. Plasma and serum were rapidly separated and frozen at -80°C for measurement of the variables of interest.

We used several surrogates to estimate pancreatic β cell function (insulin secretion) and insulin sensitivity using the Homeostasis Model Assessment---Continuous Infusion Glucose Model Assessment (HOMA-CIGMA) \[[@pone.0138646.ref031]\] and Disse indices \[[@pone.0138646.ref032]\]. The revised quantitative insulin sensitivity check index (QUICKI) was also calculated. Plasma glucose was measured by the hexokinase method (ARCHITECT^®^ system, Abbott Diagnostics, Abbott Park, IL, USA). Plasma insulin was determined by chemiluminescence (ARCHITECT^®^ system). Plasma triglycerides and free fatty acids were measured using Biomerieux kits (Biomerieux, Marcy l'Etoile, France), and total, HDL, and LDL cholesterol using Labintest kits (Labintest, Aix-en-Provence, France). Enzyme-linked immunosorbent assay (ELISA) kits were used to assay leptin, IL-6 (Quantikine^®^, R&D Systems, Oxford, UK) and adiponectin (Bühlman, Basle, Switzerland). High-sensitivity C-reactive protein (hs-CRP) was measured by immuno-nephelometry using IMMAGE Immunochemistry Systems (Beckman Coulter, Villepinte, France). Plasma levels of PAI-1 were determined using Chromolize/PAI-1 kits (Biopool International, CA, USA).

Dietary intakes were monitored by a registered dietician according to the information obtained from each subject's 3-day dietary record. All records were collected using the computer software MXS program (Medical Expert System, [www.mxs-sante.fr](http://www.mxs-sante.fr/)). Lifestyle was evaluated using the Three-Factor Eating Questionnaire \[[@pone.0138646.ref033]\] and Baecke physical activity questionnaire \[[@pone.0138646.ref034]\].

Power calculation {#sec013}
-----------------

The trial was designed to demonstrate superiority of the dietary supplement over placebo. Assuming a 7% change in FPG in the active treatment group based on internal unpublished data and a previous study \[[@pone.0138646.ref021]\], i.e. 0.39 mmol/L for changes in FPG between the dietary supplement and placebo groups during the treatment periods, with a standard deviation (SD) of 0.41 mmol/L (for changes between 4 months and baseline), a sample of 25 evaluable subjects per group was considered to have ≥90% power to detect a between-treatment difference in FPG change with a type I error rate of 5%. Assuming that 15 to 20% of subjects would be non-evaluable for the primary efficacy outcome, at least 60 subjects (30 per group) were to be included.

Statistical analysis {#sec014}
--------------------

The principal efficacy analysis was a per-protocol analysis performed on subjects who had respected the stipulated interval between visits (±10 days) and who had received at least 85% of the scheduled study treatment (compliers). A second efficacy analysis, performed for confirmatory purposes, and the safety analysis were performed on the intention-to-treat population (i.e. all randomized subjects).

Values are expressed as the mean±SD in the tables and as the mean±SEM (standard error of the mean) in the figures. Variables were tested for normality using the Shapiro-Wilk test, and subjected to logarithmic or Anscombe transformation, where appropriate, to conform to the normality assumptions (Table A in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}). A paired Student's t-test was used for comparisons between the different time points in each group, an unpaired Student's t-test being used to compare the treatment effect between the two groups. An ANCOVA adjusted for variations of fat-free mass (%) was used to check whether the observed difference in FPG level between the two groups was independent of fat-free mass.

Several exploratory *post-hoc* analyses were performed in the dietary supplement and placebo groups. In an attempt to understand the effects of the dietary supplement on FPG responses, we searched for factors potentially predictive of decreased FPG level. Correlations between changes in FPG level during the dietary supplement treatment and various clinical and biological variables at baseline were investigated using Pearson correlations.

Furthermore, in the dietary supplement group in order to classify subjects according to their ability to secrete insulin and the expected impact on FPG, the correlation between changes in FPG level and changes in insulin secretion (HOMA-B%) was tested. The baseline values of the identified two groups of subjects (separated by the correlation line) were compared using the nonparametric Mann Whitney test to identify the two different phenotypes. Correlations between changes in fat-free mass, changes in insulin sensitivity (revised QUICKI), and changes in free fatty acids were also explored.

Statistical analyses were performed using R software version 2.13 ([http://www.r-project.org](http://www.r-project.org/)), with the following R packages: plotrix 3.4--5 \[[@pone.0138646.ref035]\] and nlme 3.1--105 \[[@pone.0138646.ref036]\]. Two-tailed *p-*values of less than 0.05 were considered statistically significant.

Results {#sec015}
=======

Study population {#sec016}
----------------

Sixty-two subjects (40 women, 22 men) were selected from an initial panel of 220 screened subjects and randomized (intention-to-treat population) ([Fig 1](#pone.0138646.g001){ref-type="fig"}). Two subjects, one in each treatment group, lacked efficacy data at Month 4. Eight subjects showed non-compliance with the stipulated supplement dosage (less than 85% of the allocated treatment) or study treatment duration (10 days less or more than the allowed interval). Baseline characteristics did not differ significantly between subjects not considered in the per-protocol efficacy analysis (n = 10) and those included in this analysis (n = 52), although numerically the proportion of men was higher and mean age was lower in the former population (Table B in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}).

![Consort flow diagram.\
ITT: intention-to-treat. One subject in the dietary supplement group was lost to follow-up at Month 2, and one subject in the placebo group was withdrawn from the study at Month 2 due to a serious adverse event not related to study treatment (new condition with a need for hormonal treatment).](pone.0138646.g001){#pone.0138646.g001}

Baseline characteristics did not differ between the two treatment groups, in either the intention-to-treat or the per-protocol population ([Table 2](#pone.0138646.t002){ref-type="table"}). According to self-reported data, the subjects' lifestyle and physical activity remained unchanged throughout the study in both groups (Table C in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}).

10.1371/journal.pone.0138646.t002

###### Baseline characteristics of subjects in the intention-to-treat and per-protocol populations.

Values are mean±SD; ITT: intention-to-treat; PP: per-protocol; F: female; M: male. The baseline data in the dietary supplement and placebo groups were compared using Student's t-tests for quantitative variables and Fisher\'s exact test for sex. No statistically significant difference was found between the two treatment groups in either of the two study populations.

![](pone.0138646.t002){#pone.0138646.t002g}

                                                ITT population      PP population                                          
  --------------------------------------------- ------------------- ----------------- ------ -------------- -------------- ------------
  **Dietary control**                                                                                                      
      Energy (kcal/d)                           2037.7 ± 591.4      1883.3 ± 703.8    0.28   1989.5±448.5   1883.8±735.9   0.38
      Carbohydrates (%)                         41.9 ± 7.1          40.9 ± 8.3        0.61   42.8 ±6.7      39.6±7.8       0.13
      Protein (%)                               17.6 ± 3.5          17.6 ± 3.8        0.90   17.6±3.6       17.7±3.9       0.96
      Lipid (%)                                 37.5 ± 5.1          37.4 ± 5.8        0.90   37.1±5.5       37.9±5.8       0.59
  **Adiposity markers**                                                                                                    
      Body weight (kg)                          87.6 ± 14.4         86.1 ± 9.8        0.63   87.5±13.7      85.8±10.2      0.59
      BMI (kg/m2)                               31.6 ± 4.7          31.2 ± 3.1        0.82   31.6 ± 4.5     31.4 ± 3.1     0.95
      Fat mass (kg)                             33.7 ± 8.7          33.5 ± 6.8        0.92   33.8±9.0       34.04±7.1      0.92
      Fat mass (%)                              39.00 ± 6.4         39.8 ± 7.3        0.62   39.1±6.8       40.6±7.2       0.46
      Fat-free mass (kg)                        49.9 ± 9.1          48.4 ± 8.9        0.52   49.6±8.7       47.6±8.7       0.39
      Fat-free mass (%)                         58.1 ± 6.1          57.3 ± 7.0        0.60   58.0±6.5       56.6±6.9       0.45
      Adipocyte diameter (μm)                   111.1 ± 9.6         114.4 ± 7.2       0.14   111.3±10.5     114.0±7.3      0.30
  **Lipid Homeostasis**                                                                                                    
      Triacylglycerol (g/L)                     1.3 ± 0.5           1.3 ± 0.7         0.76   1.3±0.5        1.3±0.7        0.47
      Total cholesterol (g/L)                   2.2± 0.4            2.1 ± 0.4         0.25   2.3±0.5        2.1±0.4        0,29
      HDL cholesterol (g/L)                     0.5 ± 0.1           0.5 ± 0.2         0,18   0.5±0.1        0.6±0.2        0,07
      LDL cholesterol (g/L)                     1.5 ± 0.4           1.3 ± 0.4         0,09   1.5±0.4        1.4±0.4        0,10
      FFA (mmol/L)                              0.4 ± 0.2           0.4 ± 0.2         0.85   0.4±0.2        0.5±0.2        0.18
  **Glucose homeostasis**                                                                                                  
      Fasting Plasma glucose (mmol/L)           6.0 ± 0.6           6.1 ± 0.6         0.72   6.1±0.6        6.1±0.6        0,75
      Fasting Plasma insulin (μU/mL)            9.3 ± 5.4           9.9 ± 4.2         0.47   9.7±5.7        9.4±3.5        0,86
      HbA1c (%)                                 5.9 ± 0.4           5.9 ± 0.4         0.86   5.9±0.4        5.9±0.4        0,57
      HOMA-IR                                   1.3 ± 0.7           1.4 ± 0.6         0.46   1.3±0.8        1.3±0.5        0,84
      HOMA-S (%)                                101.4 ± 51.5        92.2 ± 57.9       0.47   99.7±54.2      95.1±59.3      0.84
      HOMA-B (%)                                73.9 ± 24.4         76.7 ± 27.2       0.68   75.0±25.4      72.3±17.6      0.83
      Revised Quicki                            0.4 ± 0.1           0.4 ± 0.04        0.48   0.4±0.1        0.4±0.04       0,29
      Disse index                               -7.6 ± 6.42         -6.8 ± 4.8        0.62   -7.7±6.8       -6.3±4.5       0,42
  **Adipokines and Inflammatory factors**                                                                                  
      Leptin (ng/mL)                            30.2 ± 22.9         31.0 ± 21.6       0.71   32.6±24.0      32.0±21.9      0.82
      Adiponectin (μg/mL)                       5.0 ± 3.4           4.5 ± 2.2         0.62   5.0±3.5        4.6±2.1        0.96
      hs-CRP(mg/L)                              5.3 ± 6.4           4.0 ± 4.3         0.49   5.9±6.8        4.0±4.3        0.35
      PAI-1 (ng/mL)                             25.8 ± 21.3         26.0 ± 20.4       0.75   26.5±22.6      25.8±20.0      0.74
      IL-6 (pg/mL)                              2.0 ± 1.3           1.9 ± 1.3         0.96   1.9±1.3        1.9±1.3        0.99
  **Adipokines explored from adipose tissue**                                                                              
      Adiponectin (pg/mL)                       10415.4 ± 10185.4   8883.2 ± 6408.2   0,87   11877±10501    9283 ±6581     0,51
      IL-6 (pg/mL)                              536.0 ± 420.2       1099.2 ± 1699.3   0,15   576 ± 446      1130 ± 1777    0,25
      Akt (arbitratry U)                        13.8 ± 14.8         11.4 ± 13.8       0,49                  15.2 ± 15.8    9.5 ± 11.5

Energy intake and body composition {#sec017}
----------------------------------

Changes in energy and in macronutrient intakes were similar in the two groups ([Table 3](#pone.0138646.t003){ref-type="table"}). Body weight and body mass index increased significantly at Month 4 in both treatment groups with no statistically significant between-group difference. However, fat-free mass increased significantly in the dietary supplement group compared to the placebo group, in terms of both percentage (p = 0.02) and absolute (p = 0.008) values.

10.1371/journal.pone.0138646.t003

###### Study variables before and after 4-month treatment with dietary supplement or placebo.

Values are expressed as mean±SD. M4: Month 4; FPG: fasting plasma glucose. FP insulin: fasting plasma insulin; HbA1c: glycated hemoglobin; HOMA-IR: homeostatic model assessment-insulin resistance; HOMA-B (%): β cell function; HOMA-S (%): insulin sensitivity; QUICKI: quantitative insulin sensitivity check index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FFA: free fatty acids; hs-CRP: high-sensitivity C-reactive protein; PAI-1: plasminogen activator inhibitor-1; IL-6: interleukin-6; Akt: serine/threonine protein kinase B. Baseline data did not differ between groups using unpaired Student t-tests. Baseline and 4-month data in each group were compared using paired Student's t-tests; Changes (values at 4 months--values at baseline/values at baseline\*100) in the placebo and dietary supplement groups were compared using unpaired Student's t-test.
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                                               Placebo (n = 26)   Dietary supplement (n = 26)   Changes in placebo vs dietary supplement                                          
  -------------------------------------------- ------------------ ----------------------------- ------------------------------------------ -------------- --------------- ------- -------
  **Dietary intake**                                                                                                                                                              
      Energy (kcal/day)                        1989.5±448.5       2045.1±611.1                  0.69                                       1883.8±735.9   1898.6±572.4    0.80    0.90
      Carbohydrates (%)                        42.8 ±6.7          42.74±7.8                     0.96                                       39.6±7.8       39.3±7.5        0.82    0.91
      Proteins (%)                             17.6±3.6           17.6±3.8                      0.91                                       17.7±3.9       17.9±3.5        0.69    0.70
      Lipids (%)                               37.1±5.5           35.7±5.8                      0.30                                       37.9±5.8       37.6±4.5        0.76    0.55
  **Glucose homeostasis**                                                                                                                                                         
      FPG (mmol/L) (mmol/L)mmol/L)             6.1±0.6            6.2±0.8                       0.36                                       6.1±0.6        5.9±0.6         0.026   0.020
      FP insulin (μU/mL)                       9.7±5.7            9.0±4.5                       0.77                                       9.4±3.5        9.9±3.9         0.25    0.33
      HbA1c (%)                                5.96±0.40          6.12±0.50                     0.00015                                    5.89±0.43      5.99±0.47       0.015   0.32
      HOMA-IR                                  1.3±0.8            1.3±0.6                       0.80                                       1.29±0.5       1.3±0.5         0.31    0.39
      HOMA-S (%)                               99.7±54.2          99.1±46.6                     0.83                                       95.1±59.3      85.7±34.1       0.31    0.41
      HOMA-B (%)                               75.0±25.4          68.4±18.4                     0.5                                        72.3±17.6      81.7±19.8       0.043   0.06
      Revised QUICKI                           0.4±0.1            0.4±0.1                       0.29                                       0.4±0.04       0.38±0.03       0.083   0.66
      Disse index                              -7.7±6.8           -7.4±6.3                      0.76                                       -6.3±4.5       -7.8±4.5        0.040   0.88
  **Lipid Homeostasis**                                                                                                                                                           
      Triacylglycerol (g/L)                    1.3±0.5            1.3±0.7                       0.52                                       1.3±0.7        1.3±0.7         0.56    0.91
      Total cholesterol (g/L)                  2.3±0.5            2.2±0.4                       0.36                                       2.1±0.4        2.1±0.4         0.86    0.49
      HDL cholesterol (g/L)                    0.5±0.1            0.5±0.2                       0.63                                       0.6±0.2        0.5±0.1         0.12    0.56
      LDL cholesterol (g/L)                    1.5±0.4            1.45±0.3                      0.41                                       1.4±0.4        1.4±0.5         0.40    0.24
      FFA (mmol/L)                             0.4±0.2            0.4±0.2                       0.11                                       0.5±0.2        0.5±0.2         0.24    0.96
  **Adiposity markers**                                                                                                                                                           
      Body weight (kg)                         87.5±13.7          88.6±14.1                     0.035                                      85.8±10.2      86.8±10.2       0.020   0.81
      Body mass index (kg/m^2^)                31.6 ± 4.5         31.9 ± 4.7                    0.035                                      31.4 ± 3.1     31.8 ± 3.2      0.014   0.79
      Fat mass (kg)                            33.8±9.0           34.5±9.4                      0.041                                      34.04±7.1      34.0±6.5        0.94    0.26
      Fat mass (%)                             39.1±6.8           39.7±7.4                      0.09                                       40.6±7.2       40.0±6.5        0.15    0.026
      Fat-free mass (kg)                       49.6±8.7           49.5±9.0                      0.58                                       47.6±8.7       48.8±8.2        0.003   0.008
      Fat-free mass (%)                        58.0±6.5           57.4±7.0                      0.09                                       56.6±6.9       57.2±6.2        0.14    0.020
      Adipocyte diameter (μm)                  111.3±10.5         111.7±10.0                    0.82                                       114.0±7.3      116.6±5.7       0.045   0.18
  **Adipokines and markers of inflammation**                                                                                                                                      
      Leptin (ng/mL)                           32.6±24.0          32.6±23.7                     0.99                                       32.0±21.9      32.9±20.9       0.35    0.54
      Adiponectin (μg/mL)                      5.0±3.5            4.6±2.2                       0.63                                       4.6±2.1        4.7±2.4         0.97    0.83
      hs-CRP (mg/L)                            5.9±6.8            6.0±8.6                       0.30                                       4.0±4.3        3.7±5.0         0.59    0.59
      PAI-1 (ng/mL)                            26.5±22.6          32.4±22.5                     0.07                                       25.8±20.0      33.1±22.2       0.11    0.85
      IL-6 (pg/mL)                             1.9±1.3            1.9±1.6                       0.48                                       1.9±1.3        1.9±1.1         0.92    0.66
  **Adipokines assayed in adipose tissue**                                                                                                                                        
      Adiponectin (pg/mL)                      11877±10501        9656 ±8068                    0.19                                       9283 ±6581     9768 ± 6628     0.72    0.38
      IL-6 (pg/mL)                             576 ± 446          929 ± 1279                    0.22                                       1130 ± 1777    1487.35 ±2120   0.24    0.92
      Akt (arbitrary U)                        15.2 ± 15.8        16.8 ± 17.5                   0.89                                       9.5 ± 11.5     16.0 ± 15.7     0.23    0.40

Plasma glucose homeostasis and insulin sensitivity surrogates {#sec018}
-------------------------------------------------------------

At Month 4, a significant decrease in FPG level was seen in the dietary supplement group (absolute changes:-0.24±0.50 mmol/L) compared to baseline (p = 0.026), whereas no change being observed in the placebo group (absolute change: +0.12±0.59 mmol/L, p = 0.36) ([Table 3](#pone.0138646.t003){ref-type="table"}). The difference between the groups was statistically significant (p = 0.02; [Table 3](#pone.0138646.t003){ref-type="table"} and Figure A in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}). At the end of follow-up (two months after treatment cessation), FPG tended to return towards baseline values in the dietary supplement group (Figure A in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}). However, three different kinetic trajectories for FPG were identified in this group (Figure B-A in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"} **)**: 1) in six subjects, FPG decreased during the treatment period (-5%), with a further decline at the end of follow-up (-11%); 2) in 11 subjects, FPG decreased during treatment (-9.7%) and then returned to baseline; 3) in nine subjects, FPG slightly increased during treatment, subsequently remaining constant throughout follow-up. In the placebo group only two different kinetic trajectories were identified (Figure B-B in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}): 1) in 17 subjects, FPG declined slightly (-2.7%) during the treatment period and remained stable throughout follow-up; 2) in nine subjects, FPG showed an elevation of 11% during the treatment period then a reduction at the end of follow-up. Kinetic trajectories in the placebo group were totally different from those observed in the treatment group: while two clusters in the dietary supplement group (representing 65% of included subjects) showed a decrease of either -5 or -10 of FPG, only one cluster in the placebo group showed a slight decrease of -2.7% in 65% of subjects.

HbA1c levels were slightly higher at Month 4 than at baseline in both groups, with no between-group difference. Whereas fasting plasma insulin level did not change within either group, insulin secretion, evaluated by HOMA-B%, increased significantly in the dietary supplement group and numerically decreased in the placebo group, with a trend towards statistical significance for the between-group comparison (p = 0.06; [Table 3](#pone.0138646.t003){ref-type="table"}). There was an improvement in insulin sensitivity in the dietary supplement group (a trend for revised QUICKI, p = 0.08 and a significant effect for Disse index, p = 0.04), but this improvement did not differ from that observed in the placebo group, whether evaluated by HOMA-IR, revised QUICKI or Disse Index.

In the dietary supplement, the decrease in FPG was negatively correlated with increased insulin secretion ([Fig 2A](#pone.0138646.g002){ref-type="fig"}) and the increase in fat-free mass was associated with increased insulin sensitivity as measured by revised QUICKI ([Fig 2B](#pone.0138646.g002){ref-type="fig"}). The correlations remained significant after adjustment by gender, age and BMI: a) adjusted correlation between changes in FPG and changes in HOMA-B (p = 0.00005, r = -0.57), b) adjusted correlation between changes in fat-free mass and changes in revised QUICKI (p = 0.038, r = 0.31), c) adjusted correlation between changes in fat-free mass and changes in free fatty acids (p = 0.0006, r = -0.46). In the placebo group, changes in FPG were also negatively correlated to changes in insulin secretion ([Fig 3A](#pone.0138646.g003){ref-type="fig"}), whereas there was no significant correlation between changes in fat-free mass and changes in insulin sensitivity ([Fig 3B](#pone.0138646.g003){ref-type="fig"}).

![Correlations between changes in FPG or fat-free mass and other bioclinical parameters during dietary supplement treatment.\
A: Correlation between changes in fasting plasma glucose and insulin secretion estimated by HOMA-B%. B: Correlations between changes in fat-free mass and changes in insulin sensitivity (estimated by revised QUICKI). C: Correlations between changes in fat-free mass and free fatty acids; N = 23 in A and B due to 3 missing data for plasma insulin, N = 26 subjects in C. Pearson correlations were used. D0: Day 0; M4: Month 4.](pone.0138646.g002){#pone.0138646.g002}

![Correlations between changes in FPG or fat-free mass and other bioclinical parameters in the placebo group.\
A: Correlation between changes in FPG and insulin secretion estimated by HOMA-B%. B: Correlations between changes in fat-free mass and changes in insulin sensitivity estimated by revised QUICKI. C: Correlations between changes in fat-free mass and free fatty acids; N = 22 in A and B due to 4 missing data for plasma insulin, N = 26 subjects in C. Pearson correlations were used. D0: Day 0; M4: Month 4.](pone.0138646.g003){#pone.0138646.g003}

Other biological parameters {#sec019}
---------------------------

No within-group changes and no between-group differences were observed with respect to plasma triglycerides, total, HDL- or LDL-cholesterol, free fatty acids, plasma adipokines, inflammatory markers or adipose tissue metabolism *in vitro* ([Table 3](#pone.0138646.t003){ref-type="table"}). In the dietary supplement group, but not in the placebo group, the increase in fat-free mass was negatively correlated with rise in plasma free fatty acid concentration (Figs [2C](#pone.0138646.g002){ref-type="fig"} and [3C](#pone.0138646.g003){ref-type="fig"}).

Findings in the intention-to-treat population {#sec020}
---------------------------------------------

Overall, the results concerning biological markers in the intention-to-treat population were similar to those seen in the per-protocol population (Table D in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}).

The rates of adverse events, as a whole, and serious adverse events did not differ significantly between the two groups (Table E in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}). None of the serious adverse events was considered to be related to the study treatment.

Factors potentially predictive of decreased FPG in the dietary supplement group {#sec021}
-------------------------------------------------------------------------------

### 1. Associations between FPG changes and baseline characteristics {#sec022}

None of the following baseline characteristics was found to be associated with decreased FPG: sex, age, physical activity, total energy intake, macronutrient categories and adiposity markers. In contrast, the greatest decreases in FPG during dietary supplement treatment were significantly associated with high baseline FPG and with low baseline IL-6 values (Figures C and D in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}).

### 2. Classification of subjects by their manifestation of changes in FPG and insulin secretion during dietary supplement intake {#sec023}

As shown in [Fig 2A](#pone.0138646.g002){ref-type="fig"}, points below the correlation line corresponded to subjects with the greatest decreases in FPG level in response to increased insulin secretion during dietary supplementation (good responders), whereas points above the line designated those whose FPG concentrations declined less than would be expected given the changes in their insulin secretion levels (poor responders). As regards the baseline characteristics of these two groups (Table F in [S1 File](#pone.0138646.s004){ref-type="supplementary-material"}), good responders had a lower mean age, a milder inflammatory state (based on plasma IL-6 level and IL-6 secretion by adipose tissue *in vitro*), and higher HDL levels. In addition, good responders tended to have higher FPG and lower plasma adiponectin levels at baseline compared to poor responders.

Discussion {#sec024}
==========

In view of the conflicting results of available clinical studies evaluating cinnamon \[[@pone.0138646.ref017]--[@pone.0138646.ref020]\] and chromium \[[@pone.0138646.ref023];[@pone.0138646.ref037]--[@pone.0138646.ref039]\], the American Diabetes Association currently considers that there is insufficient evidence to support their use in subjects with diabetes \[[@pone.0138646.ref003];[@pone.0138646.ref040]\]. Although modest, this randomized, double-blind study conducted in pre-diabetic subjects adds to the body of emerging evidence, showing that compared to placebo, treatment with a dietary supplement containing cinnamon, chromium and carnosine significantly decreased FPG levels. This beneficial effect was associated with a significant increase in fat-free mass. We included overweight or obese patients with impaired FPG who are considered to be at high risk of T2D and are assigned high priority for diabetes prevention \[[@pone.0138646.ref010]\]. The dietary supplement contained a cinnamon bark (*Cinnamomum cassia*) extract rich in polyphenol type-A polymers currently considered to be the bioactive components of cinnamon \[[@pone.0138646.ref041]\]. Concerning the type of cinnamon, *Cinnamomum zeylanicum*, however, is regarded to be more effective and safe than *Cinnamomum cassia* which is characterized by high concentrations of coumarins that may cause health risks \[[@pone.0138646.ref042];[@pone.0138646.ref043]\]. For this reason, the European Food Safety Association (EFSA) advocated in 2008 against the regular use of *Cinnamomum cassia* as a supplement in diabetes \[[@pone.0138646.ref044]\]. However, data on the efficacy of *Cinnamomum zeylanicum* in humans are sparse \[[@pone.0138646.ref045]\] and no randomized double-blinded placebo-controlled clinical trials are available to establish the therapeutic efficacy and safety of *Cinnamomum zeylanicum* as a pharmaceutical agent. On the other hand, the extract of *Cinnamomum cassia* used in the present study, can be considered safe since the daily intake of two capsules contains 0.41 mg of coumarins which is well below the tolerable daily intake of 0.1 mg/kg body weight advised by the EFSA \[[@pone.0138646.ref044]\]. The dose and type of cinnamon tested in the present study were comparable to those selected in a previous study in pre-diabetic subjects with impaired FPG \[[@pone.0138646.ref021]\] as well as those with diabetes (42). Finally, the 4-month duration of treatment in the present study is one of the longest evaluated to date for cinnamon \[[@pone.0138646.ref017]--[@pone.0138646.ref020]\] and constitutes the recommended minimal duration in trials assessing the benefits of chromium \[[@pone.0138646.ref037]\].

Of note, there was a very slight elevation of HbA1c (within the normal range) in each of the dietary supplement and placebo groups without a significant difference between the two groups. We have no obvious reason explaining this difference, except only the observed slight non-significant increase in carbohydrate intake. In addition, the favorable effect of the dietary supplement on FPG, in the present study, was not associated with any benefit with respect to HbA1c. This is in agreement with a previous study in pre-diabetic subjects (21) and with a recent meta-analysis \[[@pone.0138646.ref019]\] in T2D patients. In the meta-analysis, the only two trials showing beneficial effect of cinnamon on HbA1c included diabetic patients with HbA1c levels greater than 8% \[[@pone.0138646.ref046];[@pone.0138646.ref047]\]. In T2D subjects with controlled HbA1c levels, cinnamon failed to decrease HbA1c contrary to its effect on FPG \[[@pone.0138646.ref048]\]. Similar results were found in the pre-diabetic state with normal range of HbA1c \[[@pone.0138646.ref021]\]. It has been demonstrated that there is a poor agreement between FPG and low HbA1c values and that normal range HbA1c is less sensitive to variations in FPG \[[@pone.0138646.ref049]\]. It has been suggested that the effect of cinnamon is minimal when glucose control is closer to normal and that it exerts a significant effect in reducing FPG as the values slightly increase \[[@pone.0138646.ref050]\]. This observation is strengthened by the fact that the decrease in FPG observed in the dietary supplement group was negatively correlated with baseline FPG. Patients with the highest FPG level at baseline were those who benefited more from the dietary supplement showing thus the greatest reduction in FPG.

It may be argued that the 0.3 mmol/L difference between the changes in FPG achieved by the dietary supplement compared with placebo, in the absence of any difference in terms of HbA1c, is small and likely to have little impact on the future development of diabetes. Nevertheless, it is within the range observed in a previous study investigating the use of cinnamon alone in pre-diabetic subjects (0.5 mmol/L) \[[@pone.0138646.ref021]\]. Moreover, in intervention trials evaluating the effects of diet and exercise and/or various pharmacological agents, which showed a 30 to 70% decrease in the risk of diabetes in a much larger population with a much longer follow-up than in our study, the difference between the intervention and control groups with respect to change in FPG ranged from 0.2 mmol/L at 2.4-year follow-up to 0.9 mmol/L at 20-year follow-up \[[@pone.0138646.ref021];[@pone.0138646.ref051]--[@pone.0138646.ref056]\]. Although, in diabetic patients, traditionally available therapeutic options reduce blood glucose concentrations, and subsequently improve pancreatic beta-cell function, none of the available anti-hyperglycemic agents changes the natural progression of T2D \[[@pone.0138646.ref057]\]. However, in pre-diabetic patients as in the present study, the modest decrease in FPG will prevent the development of diabetes with its associated micro- and macrovascular complications \[[@pone.0138646.ref058];[@pone.0138646.ref059]\]. Moreover, epidemiological evidence shows that cardiovascular diseases might start at low plasma glucose levels, below the level defined for diabetes and even for impaired glucose tolerance \[[@pone.0138646.ref060];[@pone.0138646.ref061]\]. Therefore, any minor lowering of FPG levels in non-diabetic subjects will be of benefit in both preventing the progression to diabetes and lowering the risk of cardiovascular diseases.

Interestingly, 23% of subjects in our dietary supplement group showed continued improvement in FPG level after treatment cessation, a percentage approaching consistency with the 35% to 50% rate of regression to normal glucose tolerance observed in some large intervention trials \[[@pone.0138646.ref055];[@pone.0138646.ref056];[@pone.0138646.ref062]\]. The decrease in FPG seen in the dietary supplement group was negatively associated with markers of insulin secretion. This correlation allowed identification of good responders, i.e. subjects showing an appropriate decrease in FPG in response to increased insulin secretion, and their tentative phenotype. In regards to the baseline characteristics of these two groups, the good responders had a lower mean age, a milder inflammatory state (based on plasma IL-6 level and IL-6 secretion by adipose tissue *in vitro*) and higher HDL levels. In addition, good responders tended to have higher FPG and lower plasma adiponectin levels at baseline compared to poor responders. Taken together, these findings may help to identify the subjects most likely to benefit from such dietary supplementation.

The question is raised whether the increased insulin secretion in the dietary supplement group could be of benefit since increasing insulin secretion capacity is one of the main targets of clinical perspective. Main therapies for diabetes aimed indeed at restoring insulin levels either by stimulating insulin secretion or improving insulin sensitivity. Therefore, any dietary supplements that may stimulate insulin secretion would be of promising benefit in controlling FPG levels in pre-diabetic subjects. However, we are aware that the estimation of insulin secretion by indirect surrogates is not the best way to evaluate insulin secretion. Further studies are needed to confirm this finding by direct methods as frequently sampled intravenous glucose tolerance test or hyperglycemic clamps.

Another interesting finding of the present study was that the use of the dietary supplement was associated with an increase in lean mass, although there was no difference *versus* placebo with respect to food intake, body weight, body mass index and lifestyle. This finding is consistent with that reported in the only previous study in subjects with impaired FPG which showed that 12-week treatment with cinnamon (500 mg/day) improved body composition by increasing lean mass and decreasing percentage of fat mass, using the same methods as ours to measure body composition \[[@pone.0138646.ref021]\]. In that study, the increase in lean mass (+1.4 kg) was in the same range as that we observed (+1.2 kg). Another study conducted in T2D patients showed that intake of a high dose of cinnamon (3 g/day) for eight weeks was associated with a decrease in percentage of fat mass \[[@pone.0138646.ref063]\], probably owing to an increase in fat-free mass as observed in our study. We believe this finding is important considering the role of lean mass in the long-term maintenance of metabolic rate, core body temperature, skeletal integrity, muscle strength, functional capacities, and prevention of sarcopenic obesity \[[@pone.0138646.ref064]\]. Since muscle constitutes the largest portion of insulin-sensitive tissue in the body, decrease in fat-free mass may be an important factor with regard to insulin resistance and risk of T2D \[[@pone.0138646.ref065]--[@pone.0138646.ref067]\]. Our study showed no evidence of any change in insulin resistance/sensitivity indices or free fatty acid level. However, in the dietary supplement, but not in the placebo group, there was a significant within-group improvement in insulin sensitivity (revised QUICKI and Disse index), and the increase in fat-free mass was associated with increased insulin sensitivity (as measured by revised QUICKI) and was negatively correlated with increased plasma free fatty acids. Several evidences support the involvement of free fatty acids in the development of skeletal muscle insulin resistance \[[@pone.0138646.ref068]\]. Cinnamon might increase fat-free mass by several mechanisms. In the dietary supplement group, increased insulin secretion might have increased glucose uptake that enabled glycogen to be synthetized and stored. Additionally, in the presence of an adequate supply of amino acids, insulin is anabolic in muscle and may increase muscle mass. Further researches are required to elucidate the underlying mechanisms.

As in the previous study investigating the benefits of cinnamon in pre-diabetic subjects \[[@pone.0138646.ref021]\], we did not find any difference between the dietary supplement and placebo groups with respect to lipid homeostasis. This might reflect the fact that the measured parameters were already normal at baseline. Chronic inflammation appears to be a central mediator of insulin resistance associated with obesity \[[@pone.0138646.ref069]\] or pre-diabetes \[[@pone.0138646.ref070]--[@pone.0138646.ref072]\]. In our study, no difference was seen between the treatment groups in terms of inflammatory markers, an unexpected finding considering the anti-inflammatory effect of cinnamon observed in experimental studies \[[@pone.0138646.ref016]\]. In contrast, we found that the dietary supplement had a greater effect on FPG in subjects with lower baseline plasma IL6. Furthermore, a milder inflammatory state at baseline was one of the characteristics of subjects identified as good responders to increased insulin secretion.

The question as to whether the other two components of the dietary supplement played a synergistic role in our observations is difficult to ascertain. The use of chromium in the treatment of T2D has been debated \[[@pone.0138646.ref039];[@pone.0138646.ref073];[@pone.0138646.ref074]\]. Two recent meta-analyses assessing the interest of chromium supplementation in the context of diabetes led to contradictory conclusions: The first one \[[@pone.0138646.ref038]\], based on 16 clinical studies, failed to show any benefit, whereas the second one \[[@pone.0138646.ref073]\] that included 22 studies concluded favorable effects of chromium supplementation on plasma glucose control in patients with diabetes. Chromium at doses of 200 to 1000 μg/day for 2 or 4 months was shown to reduce FPG and HbA1c in patients with T2D \[[@pone.0138646.ref023]\]. However, this benefit was not seen in pre-diabetic subjects \[[@pone.0138646.ref023]\]. Meta-analyses of trials in overweight or obese patients showed that chromium was associated with statistically significant reductions in body weight and percentage body fat, although these effects were considered to be of small magnitude and uncertain clinical relevance \[[@pone.0138646.ref024];[@pone.0138646.ref037]\]. Importantly, several clinical studies showed that chromium supplementation increased lean body mass and decreased fat body mass in overweight or obese subjects \[[@pone.0138646.ref027];[@pone.0138646.ref075];[@pone.0138646.ref076]\]. In experimental studies, carnosine limited oxidative stress and inflammation, prevented protein cross-linking both in diabetic animals and in otherwise healthy aging animals, and appeared to possibly play a role in the regulation of blood glucose level via an effect on the autonomic nervous system \[[@pone.0138646.ref026];[@pone.0138646.ref077];[@pone.0138646.ref078]\]. However, no clinical data are available regarding the effect of carnosine on FPG or HbA1c.

In conclusion, a 4-month treatment with a dietary supplement containing cinnamon, chromium and carnosine decreased FPG and increased fat-free mass in overweight or obese pre-diabetic subjects. Whether the dietary supplement tested in this study can prevent the risk of T2D and related complications remains to be established in larger studies with longer treatment and follow-up durations, using clinical endpoints. Higher cinnamon doses as well as other sources of cinnamon extracts may also need to be tested.
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